BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Levy I, Sherman M. Staging of hepatocellular carcinoma: assessment of the CLIP, Okuda, and Child-Pugh staging systems in a cohort of 257 patients in Toronto. Gut. 2002;50:881-885. [PMID: 12010894 DOI: 10.1136/gut.50.6.881] [Cited by in Crossref: 171] [Cited by in F6Publishing: 158] [Article Influence: 8.6] [Reference Citation Analysis]
Number Citing Articles
1 Yegin EG, Siykhymbayev A, Eren F, Bekiroglu N, Ozdogan OC. Prognostic implication of serum vascular endothelial growth factor in advanced hepatocellular carcinoma staging. Annals of Hepatology 2013;12:915-25. [DOI: 10.1016/s1665-2681(19)31297-9] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
2 Fatourou EM, Koskinas JS. Adaptive immunity in hepatocellular carcinoma: prognostic and therapeutic implications. Expert Review of Anticancer Therapy 2014;9:1499-510. [DOI: 10.1586/era.09.103] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
3 Ishizuka M, Kubota K, Kita J, Shimoda M, Kato M, Sawada T. Impact of an inflammation-based prognostic system on patients undergoing surgery for hepatocellular carcinoma: a retrospective study of 398 Japanese patients. The American Journal of Surgery 2012;203:101-6. [DOI: 10.1016/j.amjsurg.2010.09.030] [Cited by in Crossref: 60] [Cited by in F6Publishing: 64] [Article Influence: 6.0] [Reference Citation Analysis]
4 Cheng CH, Lee CF, Wu TH, Chan KM, Chou HS, Wu TJ, Yu MC, Chen TC, Lee WC, Chen MF. Evaluation of the new AJCC staging system for resectable hepatocellular carcinoma. World J Surg Oncol. 2011;9:114. [PMID: 21958080 DOI: 10.1186/1477-7819-9-114] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 3.1] [Reference Citation Analysis]
5 An JL, Ji QH, An JJ, Masuda S, Tsuneyama K. Clinicopathological analysis of CD8-positive lymphocytes in the tumor parenchyma and stroma of hepatocellular carcinoma. Oncol Lett 2014;8:2284-90. [PMID: 25289108 DOI: 10.3892/ol.2014.2516] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
6 Lin CY, Kee KM, Wang JH, Lee CM, Chen CL, Changchien CS, Hu TH, Cheng YF, Hsu HC, Wang CC. Is the Cancer of the Liver Italian Program system an adequate weighting for survival of hepatocellular carcinoma? Evaluation of intrascore prognostic value among 36 subgroups. Liver Int. 2009;29:74-81. [PMID: 18331238 DOI: 10.1111/j.1478-3231.2008.01702.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
7 Huo TI, Huang YH, Lin HC, Wu JC, Chiang JH, Lee PC, Chang FY, Lee SD. Proposal of a modified Cancer of the Liver Italian Program staging system based on the model for end-stage liver disease for patients with hepatocellular carcinoma undergoing loco-regional therapy. Am J Gastroenterol. 2006;101:975-982. [PMID: 16573785 DOI: 10.1111/j.1572-0241.2006.00462.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 2.4] [Reference Citation Analysis]
8 Tannus RK, Almeida-Carvalho SR, Loureiro-Matos CA, Miziara-Gonzalez A, Salzedas-Netto AA, Szejnfeld D, D'Ippolito G, Pereira-Lanzoni V, Souza-Silva I. Evaluation of survival of patients with hepatocellular carcinoma: A comparative analysis of prognostic systems. PLoS One 2018;13:e0194922. [PMID: 29617435 DOI: 10.1371/journal.pone.0194922] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
9 Shindoh J, Vauthey JN. Staging of biliary tract and primary liver tumors. Surg Oncol Clin N Am. 2014;23:313-322. [PMID: 24560112 DOI: 10.1016/j.soc.2013.11.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
10 Abdel-Rahman OM, Elsayed Z. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 2016;2:CD011313. [PMID: 26905230 DOI: 10.1002/14651858.CD011313.pub2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
11 Kinoshita A, Onoda H, Fushiya N, Koike K, Nishino H, Tajiri H. Staging systems for hepatocellular carcinoma: Current status and future perspectives. World J Hepatol 2015; 7(3): 406-424 [PMID: 25848467 DOI: 10.4254/wjh.v7.i3.406] [Cited by in Crossref: 68] [Cited by in F6Publishing: 62] [Article Influence: 9.7] [Reference Citation Analysis]
12 Chua DW, Koh YX, Syn NL, Chuan TY, Yao TJ, Lee SY, Goh BKP, Cheow PC, Chung AY, Chan CY. Repeat hepatectomy versus radiofrequency ablation in management of recurrent hepatocellular carcinoma: an average treatment effect analysis. Ann Surg Oncol 2021. [PMID: 33969464 DOI: 10.1245/s10434-021-09948-2] [Reference Citation Analysis]
13 Kaseb AO, Abbruzzese JL, Vauthey JN, Aloia TA, Abdalla EK, Hassan MM, Lin E, Xiao L, El-Deeb AS, Rashid A. I-CLIP: improved stratification of advanced hepatocellular carcinoma patients by integrating plasma IGF-1 into CLIP score. Oncology. 2011;80:373-381. [PMID: 21822028 DOI: 10.1159/000329040] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
14 Cho CS, Gonen M, Shia J, Kattan MW, Klimstra DS, Jarnagin WR, D’Angelica MI, Blumgart LH, DeMatteo RP. A novel prognostic nomogram is more accurate than conventional staging systems for predicting survival after resection of hepatocellular carcinoma. J Am Coll Surg. 2008;206:281-291. [PMID: 18222381 DOI: 10.1016/j.jamcollsurg.2007.07.031] [Cited by in Crossref: 83] [Cited by in F6Publishing: 83] [Article Influence: 5.5] [Reference Citation Analysis]
15 Cillo U, Bassanello M, Vitale A, Grigoletto FA, Burra P, Fagiuoli S, D'amico F, Ciarleglio FA, Boccagni P, Brolese A, Zanus G, D'amico DF. The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available? Journal of Hepatology 2004;40:124-31. [DOI: 10.1016/j.jhep.2003.09.027] [Cited by in Crossref: 133] [Cited by in F6Publishing: 122] [Article Influence: 7.4] [Reference Citation Analysis]
16 Unitt E, Rushbrook SM, Marshall A, Davies S, Gibbs P, Morris LS, Coleman N, Alexander GJ. Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells. Hepatology. 2005;41:722-730. [PMID: 15791620 DOI: 10.1002/hep.20644] [Cited by in Crossref: 192] [Cited by in F6Publishing: 185] [Article Influence: 11.3] [Reference Citation Analysis]
17 Elmeliegy M, Yang DZ, Salama E, Parivar K, Wang DD. Discordance Between Child-Pugh and National Cancer Institute Classifications for Hepatic Dysfunction: Implications on Dosing Recommendations for Oncology Compounds. J Clin Pharmacol 2021;61:105-15. [PMID: 32691438 DOI: 10.1002/jcph.1702] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
18 Bonnetain F, Paoletti X, Collette S, Doffoel M, Bouché O, Raoul JL, Rougier P, Masskouri F, Barbare JC, Bedenne L. Quality of life as a prognostic factor of overall survival in patients with advanced hepatocellular carcinoma: results from two French clinical trials. Qual Life Res 2008;17:831-43. [PMID: 18618292 DOI: 10.1007/s11136-008-9365-y] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 2.9] [Reference Citation Analysis]
19 Kim DH, Cho E, Cho SB, Choi SK, Kim S, Yu J, Koh YI, Sim DW, Jun CH. Complete response of hepatocellular carcinoma with right atrium and pulmonary metastases treated by combined treatments (a possible treatment effect of natural killer cell): A case report and literature review. Medicine (Baltimore) 2018;97:e12866. [PMID: 30334999 DOI: 10.1097/MD.0000000000012866] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
20 Kudo M. International comparison of treatment outcomes based on staging systems. Hepatol Res 2007;37 Suppl 2:S216-22. [PMID: 17877486 DOI: 10.1111/j.1872-034X.2007.00188.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
21 Tyson GL, Duan Z, Kramer JR, Davila JA, Richardson PA, El-Serag HB. Level of α-fetoprotein predicts mortality among patients with hepatitis C-related hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2011;9:989-994. [PMID: 21820396 DOI: 10.1016/j.cgh.2011.07.026] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
22 Kim NY, Sun JM, Kim YJ, Lee KW, Kim JH, Bang SM, Kim JW, Jeong SH, Lee JS. Cisplatin-Based Combination Chemotherapy for Advanced Hepatocellular Carcinoma: A Single Center Experience before the Sorafenib Era. Cancer Res Treat 2010;42:203-9. [PMID: 21253322 DOI: 10.4143/crt.2010.42.4.203] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
23 Nagai H, Kanayama M, Higami K, Momiyama K, Ikoma A, Okano N, Matsumaru K, Watanabe M, Ishii K, Sumino Y, Miki K. Twenty-four hour intra-arterial infusion of 5-fluorouracil, cisplatin, and leucovorin is more effective than 6-hour infusion for advanced hepatocellular carcinoma. World J Gastroenterol 2007; 13(2): 280-284 [PMID: 17226909 DOI: 10.3748/wjg.v13.i2.280] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
24 Goin JE, Salem R, Carr BI, Dancey JE, Soulen MC, Geschwind JF, Goin K, Van Buskirk M, Thurston K. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: a risk-stratification analysis. J Vasc Interv Radiol. 2005;16:195-203. [PMID: 15713920 DOI: 10.1097/01.rvi.0000142602.79459.90] [Cited by in Crossref: 87] [Cited by in F6Publishing: 19] [Article Influence: 5.1] [Reference Citation Analysis]
25 Marrero JA, Fontana RJ, Barrat A, Askari F, Conjeevaram HS, Su GL, Lok AS. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology. 2005;41:707-716. [PMID: 15795889 DOI: 10.1002/hep.20636] [Cited by in Crossref: 443] [Cited by in F6Publishing: 405] [Article Influence: 26.1] [Reference Citation Analysis]
26 Huo TI, Huang YH, Lee SD, Wu JC. Is there an ideal prognostic model for hepatocellular carcinoma? Gut 2005;54:1348. [PMID: 16099811 DOI: 10.1136/gut.2005.069468] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
27 Giannini E, Risso D, Botta F, Romagnoli P, Malfatti F, Fumagalli A, Testa E, Podestà E, Chiarbonello B, Polegato S, Testa R. Prognosis of hepatocellular carcinoma in anti-HCV positive cirrhotic patients: a single-centre comparison amongst four different staging systems. J Intern Med 2004;255:399-408. [PMID: 14871465 DOI: 10.1046/j.1365-2796.2003.01284.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
28 Miyazaki M, Kimura F, Shimizu H, Yoshidome H, Ohtsuka M, Kato A, Yoshitomi H, Nozawa S, Furukawa K, Takeuchi D. Surgical treatment for liver cancer. Current issues. Dig Surg. 2007;24:120-125. [PMID: 17446706 DOI: 10.1159/000101899] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
29 Yamagiwa K, Shiraki K, Yamakado K, Mizuno S, Hori T, Yagi S, Hamada T, Iida T, Nakamura I, Fujii K, Usui M, Isaji S, Ito K, Tagawa S, Takeda K, Yokoi H, Noguchi T. Survival rates according to the Cancer of the Liver Italian Program scores of 345 hepatocellular carcinoma patients after multimodality treatments during a 10-year period in a retrospective study. J Gastroenterol Hepatol. 2008;23:482-490. [PMID: 18086115 DOI: 10.1111/j.1440-1746.2007.05262.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
30 Kaseb AO, Hassan MM, Lin E, Xiao L, Kumar V, Pathak P, Lozano R, Rashid A, Abbruzzese JL, Morris JS. V-CLIP: Integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatocellular carcinoma for clinical trials. Cancer. 2011;117:2478-2488. [PMID: 24048796 DOI: 10.1002/cncr.25791] [Cited by in Crossref: 25] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis]
31 Van Deusen MA, Abdalla EK, Vauthey JN, Roh MS. Staging classifications for hepatocellular carcinoma. Expert Rev Mol Diagn 2005;5:377-83. [PMID: 15934814 DOI: 10.1586/14737159.5.3.377] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
32 Mazzoccoli G, Tarquini R, Valoriani A, Oben J, Vinciguerra M, Marra F. Management strategies for hepatocellular carcinoma: old certainties and new realities. Clin Exp Med 2016;16:243-56. [PMID: 26077653 DOI: 10.1007/s10238-015-0368-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
33 Choi HJ, Kim DG, Na GH, Han JH, Hong TH, You YK. Clinical outcome in patients with hepatocellular carcinoma after living-donor liver transplantation. World J Gastroenterol 2013; 19(29): 4737-4744 [PMID: 23922471 DOI: 10.3748/wjg.v19.i29.4737] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
34 Ahmed O, Vachharajani N, Chang SH, Park Y, Khan AS, Chapman WC, Doyle MB. Access to Liver Transplantation for Hepatocellular Carcinoma: Does Candidate Age Matter? J Am Coll Surg 2021;233:140-51. [PMID: 33652155 DOI: 10.1016/j.jamcollsurg.2021.01.018] [Reference Citation Analysis]
35 Chen CH, Hu FC, Huang GT, Lee PH, Tsang YM, Cheng AL, Chen DS, Wang JD, Sheu JC. Applicability of staging systems for patients with hepatocellular carcinoma is dependent on treatment method--analysis of 2010 Taiwanese patients. Eur J Cancer. 2009;45:1630-1639. [PMID: 19157858 DOI: 10.1016/j.ejca.2008.12.025] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 4.3] [Reference Citation Analysis]
36 Guglielmi A, Ruzzenente A, Pachera S, Valdegamberi A, Sandri M, D’Onofrio M, Iacono C. Comparison of seven staging systems in cirrhotic patients with hepatocellular carcinoma in a cohort of patients who underwent radiofrequency ablation with complete response. Am J Gastroenterol. 2008;103:597-604. [PMID: 17970836 DOI: 10.1111/j.1572-0241.2007.01604.x] [Cited by in Crossref: 70] [Cited by in F6Publishing: 66] [Article Influence: 4.7] [Reference Citation Analysis]
37 Tsai AL, Burke CT, Kennedy AS, Moore DT, Mauro MA, Dixon RD, Stavas JM, Bernard SA, Khandani AH, O’Neil BH. Use of yttrium-90 microspheres in patients with advanced hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol. 2010;21:1377-1384. [PMID: 20691606 DOI: 10.1016/j.jvir.2010.04.027] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 2.8] [Reference Citation Analysis]
38 Wildi S, Pestalozzi BC, McCormack L, Clavien PA. Critical evaluation of the different staging systems for hepatocellular carcinoma. Br J Surg 2004;91:400-8. [PMID: 15048738 DOI: 10.1002/bjs.4554] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 2.9] [Reference Citation Analysis]
39 Moriyama M, Matsumura H, Fukushima A, Ohkido K, Arakawa Y, Nirei K, Yamagami H, Kaneko M, Tanaka N, Arakawa Y. Clinical significance of evaluation of serum zinc concentrations in C-viral chronic liver disease. Dig Dis Sci. 2006;51:1967-1977. [PMID: 17048113 DOI: 10.1007/s10620-005-9051-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
40 Huang BS, Tsang NM, Lin SM, Lin DY, Lien JM, Lin CC, Chen WT, Chen WY, Hong JH. High-dose hypofractionated X-ray radiotherapy for hepatocellular carcinoma: Tumor responses and toxicities. Oncol Lett 2013;6:1514-20. [PMID: 24179551 DOI: 10.3892/ol.2013.1582] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
41 Parmiani G, Anichini A. T cell infiltration and prognosis in HCC patients. Journal of Hepatology 2006;45:178-81. [DOI: 10.1016/j.jhep.2006.06.005] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
42 Bartlett ASJR, McCall JL, Koea JB, Holden A, Yeong ML, Gurusinghe N, Gane E. Liver resection for hepatocellular carcinoma in a hepatitis B endemic area. World J Surg 2007;31:1775-81. [PMID: 17610112 DOI: 10.1007/s00268-007-9069-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
43 Gomaa AI, Hashim MS, Waked I. Comparing staging systems for predicting prognosis and survival in patients with hepatocellular carcinoma in Egypt. PLoS One 2014;9:e90929. [PMID: 24603710 DOI: 10.1371/journal.pone.0090929] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 5.1] [Reference Citation Analysis]
44 Carr BI, Buch SC, Kondragunta V, Pancoska P, Branch RA. Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: a case cohort study. J Gastroenterol Hepatol. 2008;23:1259-1266. [PMID: 18699979 DOI: 10.1111/j.1440-1746.2008.05487.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 1.8] [Reference Citation Analysis]
45 Chan SL, Yeo W. Selecting the right patients for testing novel agents in hepatocellular carcinoma: who, when and how? Asia Pac J Clin Oncol. 2013;9:2-5. [PMID: 23418846 DOI: 10.1111/ajco.12061] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
46 Goin JE, Salem R, Carr BI, Dancey JE, Soulen MC, Geschwind JF, Goin K, Van Buskirk M, Thurston K. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicities. J Vasc Interv Radiol. 2005;16:205-213. [PMID: 15713921 DOI: 10.1097/01.rvi.00001142592.89564.f9] [Cited by in Crossref: 130] [Cited by in F6Publishing: 32] [Article Influence: 7.6] [Reference Citation Analysis]
47 Fouad M, Abdel-Rahman O. Combination of transarterial chemoembolisation (TACE) plus antivirals for the management of hepatitis B-related hepatocellular carcinoma: A systematic review of the literature. Arab J Gastroenterol 2015;16:40-5. [PMID: 25910573 DOI: 10.1016/j.ajg.2015.03.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
48 Maida M, Orlando E, Cammà C, Cabibbo G. Staging systems of hepatocellular carcinoma: A review of literature. World J Gastroenterol 2014; 20(15): 4141-4150 [PMID: 24764652 DOI: 10.3748/wjg.v20.i15.4141] [Cited by in CrossRef: 61] [Cited by in F6Publishing: 56] [Article Influence: 7.6] [Reference Citation Analysis]
49 Huang YH, Chen CH, Chang TT, Chen SC, Wang SY, Lee PC, Lee HS, Lin PW, Huang GT, Sheu JC. The role of transcatheter arterial embolization in patients with resectable hepatocellular carcinoma: a nation-wide, multicenter study. Liver Int. 2004;24:419-424. [PMID: 15482337 DOI: 10.1111/j.1478-3231.2004.0941.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
50 Kaseb AO, Shah NN, Hassabo HM, Morris JS, Xiao L, Abaza YM, Soliman K, Lee JS, Vauthey JN, Wallace M. Reassessing hepatocellular carcinoma staging in a changing patient population. Oncology. 2014;86:63-71. [PMID: 24401634 DOI: 10.1159/000356573] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
51 Grosfeld JL, Otte J. Liver Tumors in Children. In: Carachi R, Grosfeld JL, Azmy AF, editors. The Surgery of Childhood Tumors. Berlin: Springer Berlin Heidelberg; 2008. pp. 227-60. [DOI: 10.1007/978-3-540-29734-5_12] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
52 Memon K, Kulik LM, Lewandowski RJ, Wang E, Wang J, Ryu RK, Hickey R, Vouche M, Baker T, Ganger D. Comparative study of staging systems for hepatocellular carcinoma in 428 patients treated with radioembolization. J Vasc Interv Radiol. 2014;25:1056-1066. [PMID: 24613269 DOI: 10.1016/j.jvir.2014.01.010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
53 Lin CT, Hsu KF, Chen TW, Yu JC, Chan DC, Yu CY, Hsieh TY, Fan HL, Kuo SM, Chung KP, Hsieh CB. Comparing hepatic resection and transarterial chemoembolization for Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma: change for treatment of choice? World J Surg. 2010;34:2155-2161. [PMID: 20407768 DOI: 10.1007/s00268-010-0598-x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 65] [Article Influence: 5.0] [Reference Citation Analysis]
54 Abdel-rahman O, Elsayed ZA. Combination Trans Arterial Chemoembolization (TACE) Plus Sorafenib for the Management of Unresectable Hepatocellular Carcinoma: A Systematic Review of the Literature. Dig Dis Sci 2013;58:3389-96. [DOI: 10.1007/s10620-013-2872-x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 50] [Article Influence: 5.6] [Reference Citation Analysis]
55 Moety HAA, Moety AAE, sayed PE. Evaluation of serum nitric oxide before and after local radiofrequency thermal ablation for hepatocellular carcinoma. Alexandria Journal of Medicine 2013;49:67-73. [DOI: 10.1016/j.ajme.2012.08.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
56 Blank S, Wang Q, Fiel MI, Luan W, Kim KW, Kadri H, Mandeli J, Hiotis SP. Assessing prognostic significance of preoperative alpha-fetoprotein in hepatitis B-associated hepatocellular carcinoma: normal is not the new normal. Ann Surg Oncol. 2014;21:986-994. [PMID: 24232510 DOI: 10.1245/s10434-013-3357-z] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 3.4] [Reference Citation Analysis]
57 Daniele B, Annunziata M, Barletta E, Tinessa V, Di Maio M. Cancer of the Liver Italian Program (CLIP) score for staging hepatocellular carcinoma. Hepatology Research 2007;37:S206-9. [DOI: 10.1111/j.1872-034x.2007.00186.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
58 Borzio M, Colloredo G, Pioltelli P, Quagliuolo M. Epidemiology and outcome of hepatocellular carcinoma in Lombardy. Dig Liver Dis. 2007;39:1011-1017. [PMID: 17936698 DOI: 10.1016/j.dld.2007.06.018] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
59 Ishizuka M, Kubota K, Kita J, Shimoda M, Kato M, Sawada T. Usefulness of a modified inflammation-based prognostic system for predicting postoperative mortality of patients undergoing surgery for primary hepatocellular carcinoma. J Surg Oncol. 2011;103:801-806. [PMID: 21240991 DOI: 10.1002/jso.21857] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 2.9] [Reference Citation Analysis]
60 Kim GA, Shim JH, Yoon SM, Jung J, Kim JH, Ryu MH, Ryoo BY, Kang YK, Lee D, Kim KM, Lim YS, Lee HC, Chung YH, Lee YS. Comparison of chemoembolization with and without radiation therapy and sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis. J Vasc Interv Radiol. 2015;26:320-9.e6. [PMID: 25612807 DOI: 10.1016/j.jvir.2014.10.019] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 6.0] [Reference Citation Analysis]
61 Abdel-Rahman O. Assessment of the discriminating value of the 8th AJCC stage grouping for hepatocellular carcinoma. HPB (Oxford). 2018;20:41-48. [PMID: 28882455 DOI: 10.1016/j.hpb.2017.08.017] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
62 Testa R, Testa E, Giannini E, Botta F, Malfatti F, Chiarbonello B, Fumagalli A, Polegato S, Podesta E, Romagnoli P. Trans-catheter arterial chemoembolisation for hepatocellular carcinoma in patients with viral cirrhosis: role of combined staging systems, Cancer Liver Italian Program (CLIP) and Model for End-stage Liver Disease (MELD), in predicting outcome after treatment. Aliment Pharmacol Ther. 2003;17:1563-1569. [PMID: 12823161 DOI: 10.1046/j.1365-2036.2003.01647.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 2.2] [Reference Citation Analysis]
63 Moriyama M, Matsumura H, Shioda J, Aoki H, Nakamura H, Arakawa Y, Nirei K, Yamagami H, Kaneko M, Tanaka N. Measurement of human intercellular adhesion molecule 1 in the blood is useful for predicting the occurrence of hepatocellular carcinomas from chronic hepatitis C and liver cirrhosis. Intervirology. 2006;49:327-338. [PMID: 16926545 DOI: 10.1159/000095152] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
64 Chan SL, Mo FK, Johnson PJ, Liem GS, Chan TC, Poon MC, Ma BB, Leung TW, Lai PB, Chan AT. Prospective validation of the Chinese University Prognostic Index and comparison with other staging systems for hepatocellular carcinoma in an Asian population. J Gastroenterol Hepatol. 2011;26:340-347. [PMID: 21261725 DOI: 10.1111/j.1440-1746.2010.06329.x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 57] [Article Influence: 5.3] [Reference Citation Analysis]
65 Fründt T, Krause L, Hussey E, Steinbach B, Köhler D, von Felden J, Schulze K, Lohse AW, Wege H, Schwarzenbach H. Diagnostic and Prognostic Value of miR-16, miR-146a, miR-192 and miR-221 in Exosomes of Hepatocellular Carcinoma and Liver Cirrhosis Patients. Cancers (Basel) 2021;13:2484. [PMID: 34069692 DOI: 10.3390/cancers13102484] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
66 Hsu KF, Chu CH, Chan DC, Yu JC, Shih ML, Hsieh HF, Hsieh TY, Yu CY, Hsieh CB. Superselective transarterial chemoembolization vs hepatic resection for resectable early-stage hepatocellular carcinoma in patients with Child-Pugh class a liver function. Eur J Radiol. 2012;81:466-471. [PMID: 21376495 DOI: 10.1016/j.ejrad.2010.12.058] [Cited by in Crossref: 31] [Cited by in F6Publishing: 40] [Article Influence: 2.8] [Reference Citation Analysis]
67 Liu PH, Hsu CY, Hsia CY, Lee YH, Su CW, Huang YH, Lee FY, Lin HC, Huo TI. Prognosis of hepatocellular carcinoma: Assessment of eleven staging systems. J Hepatol. 2016;64:601-608. [PMID: 26551516 DOI: 10.1016/j.jhep.2015.10.029] [Cited by in Crossref: 115] [Cited by in F6Publishing: 126] [Article Influence: 16.4] [Reference Citation Analysis]
68 Tournoux-Facon C, Paoletti X, Barbare JC, Bouché O, Rougier P, Dahan L, Lombard-Bohas C, Faroux R, Raoul JL, Bedenne L. Development and validation of a new prognostic score of death for patients with hepatocellular carcinoma in palliative setting. J Hepatol. 2011;54:108-114. [PMID: 21047696 DOI: 10.1016/j.jhep.2010.06.015] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
69 Salem R, Lewandowski R, Roberts C, Goin J, Thurston K, Abouljoud M, Courtney A. Use of Yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis. J Vasc Interv Radiol. 2004;15:335-345. [PMID: 15064336 DOI: 10.1097/01.rvi.0000123319.20705.92] [Cited by in Crossref: 150] [Cited by in F6Publishing: 48] [Article Influence: 8.3] [Reference Citation Analysis]
70 Yang T, Zhang J, Lu JH, Yang LQ, Yang GS, Wu MC, Yu WF. A new staging system for resectable hepatocellular carcinoma: comparison with six existing staging systems in a large Chinese cohort. J Cancer Res Clin Oncol. 2011;137:739-750. [PMID: 20607551 DOI: 10.1007/s00432-010-0935-3] [Cited by in Crossref: 33] [Cited by in F6Publishing: 37] [Article Influence: 2.8] [Reference Citation Analysis]
71 Kung J, Macdougall M, Madhavan K, Garden O, Parks R. Predicting survival in patients with hepatocellular carcinoma: A UK perspective. European Journal of Surgical Oncology (EJSO) 2007;33:188-94. [DOI: 10.1016/j.ejso.2006.10.018] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
72 Csikesz NG, Nguyen LN, Tseng JF, Shah SA. Nationwide volume and mortality after elective surgery in cirrhotic patients. J Am Coll Surg. 2009;208:96-103. [PMID: 19228510 DOI: 10.1016/j.jamcollsurg.2008.09.006] [Cited by in Crossref: 119] [Cited by in F6Publishing: 88] [Article Influence: 8.5] [Reference Citation Analysis]
73 Pawlik TM, Tseng JF, Vauthey J. Controversies in the Staging of Hepatocellular Carcinoma. Cancer Rev A P 2003;01:179-89. [DOI: 10.1142/s0219836303000220] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
74 Huo T, Lin H, Hsia C, Wu J, Lee P, Chi C, Lee S. The Model for End-Stage Liver Disease Based Cancer Staging Systems Are Better Prognostic Models for Hepatocellular Carcinoma: A Prospective Sequential Survey. Am J Gastroenterology 2007;102:1920-30. [DOI: 10.1111/j.1572-0241.2007.01370.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 3.3] [Reference Citation Analysis]
75 Burns JM, Greene FL. Controversies in staging of hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 2005;12:456-62. [DOI: 10.1007/s00534-005-1030-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
76 Gao J, Jia WD. Expression of Rho Guanine Nucleotide Exchange Factor 39 (ARHGEF39) and Its Prognostic Significance in Hepatocellular Carcinoma. Med Sci Monit 2019;25:7826-35. [PMID: 31626606 DOI: 10.12659/MSM.918270] [Reference Citation Analysis]
77 Siddique I, El-Naga HA, Memon A, Thalib L, Hasan F, Al-Nakib B. CLIP score as a prognostic indicator for hepatocellular carcinoma: experience with patients in the Middle East. Eur J Gastroenterol Hepatol. 2004;16:675-680. [PMID: 15201581 DOI: 10.1097/01.meg.0000108338.41221.ec] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
78 Stone MJ, Fulmer JM, Klintmalm GB. Transplantation for Primary Hepatic Malignancy. Transplantation of the Liver. Elsevier; 2005. pp. 211-31. [DOI: 10.1016/b978-0-7216-0118-2.50020-3] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
79 Pascual S, Zapater P, Such J, Garcia-herola A, Sempere L, Irurzun J, Palazon JM, Carnicer F, Perez-mateo M. Comparison of staging systems to predict survival in hepatocellular carcinoma. Liver Int 2006;26:673-9. [DOI: 10.1111/j.1478-3231.2006.01282.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.3] [Reference Citation Analysis]
80 Nanashima A, Morino S, Yamaguchi H, Tanaka K, Shibasaki S, Tsuji T, Hidaka S, Sawai T, Yasutake T, Nakagoe T. Modified CLIP using PIVKA-II for evaluating prognosis after hepatectomy for hepatocellular carcinoma. European Journal of Surgical Oncology (EJSO) 2003;29:735-42. [DOI: 10.1016/j.ejso.2003.08.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
81 Budhu A, Jia HL, Forgues M, Liu CG, Goldstein D, Lam A, Zanetti KA, Ye QH, Qin LX, Croce CM, Tang ZY, Wang XW. Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology. 2008;47:897-907. [PMID: 18176954 DOI: 10.1002/hep.22160] [Cited by in Crossref: 513] [Cited by in F6Publishing: 500] [Article Influence: 36.6] [Reference Citation Analysis]
82 Daniele B, Perrone F. Staging for Liver Cancer. Clinics in Liver Disease 2005;9:213-23. [DOI: 10.1016/j.cld.2004.12.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
83 Zhou ZR, Liu M, Lu HR, Li YF, Liang SX, Zhang CY. Validation of different staging systems for hepatocellular carcinoma in a cohort of 249 patients undergoing radiotherapy. Oncotarget 2017;8:46523-31. [PMID: 28147327 DOI: 10.18632/oncotarget.14881] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
84 Chen TW, Chu CM, Yu JC, Chen CJ, Chan DC, Liu YC, Hsieh CB. Comparison of clinical staging systems in predicting survival of hepatocellular carcinoma patients receiving major or minor hepatectomy. Eur J Surg Oncol. 2007;33:480-487. [PMID: 17129701 DOI: 10.1016/j.ejso.2006.10.012] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
85 Duseja A. Staging of hepatocellular carcinoma. J Clin Exp Hepatol 2014;4:S74-9. [PMID: 25755615 DOI: 10.1016/j.jceh.2014.03.045] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 5.0] [Reference Citation Analysis]
86 Li H, Huang W, Luo R. The microRNA-325 inhibits hepatocellular carcinoma progression by targeting high mobility group box 1. Diagn Pathol 2015;10:117. [PMID: 26194496 DOI: 10.1186/s13000-015-0323-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
87 Hansmann J, Ray CE Jr. Overview of Staging Systems for Hepatocellular Carcinoma and Implications for Interventional Radiology. Semin Intervent Radiol 2017;34:213-9. [PMID: 28579689 DOI: 10.1055/s-0037-1602757] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
88 Cormier J, Thomas K, Chari R, Pinson C. Management of Hepatocellular Carcinoma. Journal of Gastrointestinal Surgery 2006;10:761-80. [DOI: 10.1016/j.gassur.2005.10.006] [Cited by in Crossref: 60] [Cited by in F6Publishing: 54] [Article Influence: 3.8] [Reference Citation Analysis]
89 op den Winkel M, Nagel D, Sappl J, op den Winkel P, Lamerz R, Zech CJ, Straub G, Nickel T, Rentsch M, Stieber P. Prognosis of patients with hepatocellular carcinoma. Validation and ranking of established staging-systems in a large western HCC-cohort. PLoS One. 2012;7:e45066. [PMID: 23071507 DOI: 10.1371/journal.pone.0045066] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 3.8] [Reference Citation Analysis]
90 White SA, Manas DM, Farid SG, Prasad KR. Optimal treatment for hepatocellular carcinoma in the cirrhotic liver. Ann R Coll Surg Engl 2009;91:545-50. [PMID: 19833013 DOI: 10.1308/003588409X464649] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
91 Strazzabosco M, Cohen E, Emre S. Prognostic prediction in hepatocellular carcinoma: from art to science. J Clin Gastroenterol 2008;42:221-3. [PMID: 18223506 DOI: 10.1097/MCG.0b013e31815ed0a9] [Reference Citation Analysis]
92 Wu CH, Liang PC, Hsu CH, Chang FT, Shao YY, Ting-Fang Shih T. Total skeletal, psoas and rectus abdominis muscle mass as prognostic factors for patients with advanced hepatocellular carcinoma. J Formos Med Assoc 2021;120:559-66. [PMID: 32651043 DOI: 10.1016/j.jfma.2020.07.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
93 Ueda H, Fukuchi H, Tanaka C. Toxicity and efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma (Review). Oncol Lett. 2012;3:259-263. [PMID: 22740891 DOI: 10.3892/ol.2011.469] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
94 Contreras CM, Vauthey JN. Staging systems: Is there a surgical staging and a medical one? A surgeon's perspective. J Hepatobiliary Pancreat Sci 2010;17:438-9. [PMID: 19882373 DOI: 10.1007/s00534-009-0243-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
95 Ota H, Nagano H, Sakon M, Eguchi H, Kondo M, Yamamoto T, Nakamura M, Damdinsuren B, Wada H, Marubashi S, Miyamoto A, Dono K, Umeshita K, Nakamori S, Wakasa K, Monden M. Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression. Br J Cancer. 2005;93:557-564. [PMID: 16106266 DOI: 10.1038/sj.bjc.6602742] [Cited by in Crossref: 114] [Cited by in F6Publishing: 101] [Article Influence: 6.7] [Reference Citation Analysis]
96 Huo TI, Huang YH. Staging for hepatocellular carcinoma: treatment strategy matters. Hepatology 2005;41:678; author reply 678-9. [PMID: 15723331 DOI: 10.1002/hep.20583] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
97 Shen H, Agarwal D, Qi R, Chalasani N, Liangpunsakul S, Lumeng L, Yoo H, Kwo P. Predictors of outcome in patients with unresectable hepatocellular carcinoma receiving transcatheter arterial chemoembolization. Aliment Pharmacol Ther. 2007;26:393-400. [PMID: 17635374 DOI: 10.1111/j.1365-2036.2007.03395.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
98 Kang HY, Shin HD, Kim SB, Song IH. Prognosis predictability of hepatocellular carcinoma according to staging systems in hepatitis B virus-endemic area. Clin Res Hepatol Gastroenterol 2012;36:357-64. [PMID: 22326248 DOI: 10.1016/j.clinre.2011.12.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
99 Makary MS, Khandpur U, Cloyd JM, Mumtaz K, Dowell JD. Locoregional Therapy Approaches for Hepatocellular Carcinoma: Recent Advances and Management Strategies. Cancers (Basel) 2020;12:E1914. [PMID: 32679897 DOI: 10.3390/cancers12071914] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
100 Grieco A, Pompili M, Caminiti G, Miele L, Covino M, Alfei B, Rapaccini GL, Gasbarrini G. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut 2005;54:411-8. [PMID: 15710992 DOI: 10.1136/gut.2004.048124] [Cited by in Crossref: 173] [Cited by in F6Publishing: 162] [Article Influence: 10.2] [Reference Citation Analysis]
101 Molla N, AlMenieir N, Simoneau E, Aljiffry M, Valenti D, Metrakos P, Boucher LM, Hassanain M. The role of interventional radiology in the management of hepatocellular carcinoma. Curr Oncol. 2014;21:e480-e492. [PMID: 24940108 DOI: 10.3747/co.21.1829] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 4.1] [Reference Citation Analysis]
102 Cheung TK, Lai CL, Wong BC, Fung J, Yuen MF. Clinical features, biochemical parameters, and virological profiles of patients with hepatocellular carcinoma in Hong Kong. Aliment Pharmacol Ther. 2006;24:573-583. [PMID: 16907890 DOI: 10.1111/j.1365-2036.2006.03029.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 50] [Article Influence: 3.1] [Reference Citation Analysis]
103 Walling AM, Schreibeis-Baum H, Pimstone N, Asch SM, Robinson L, Korlekar S, Lorenz K, Nwajuaku T, Rosenfeld K. Proactive case finding to improve concurrently curative and palliative care in patients with end-stage liver disease. J Palliat Med. 2015;18:378-381. [PMID: 25493552 DOI: 10.1089/jpm.2014] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
104 Mikami E, Kanno N, Ueno Y, Shimosegawa T. Retrospective evaluation of tumor-mass-reduction therapy for the prognosis of recurrent hepatocellular carcinoma. Hepatol Int 2007;1:460-8. [PMID: 19669343 DOI: 10.1007/s12072-007-9021-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
105 Addissie BD, Roberts LR. Classification and staging of hepatocellular carcinoma: an aid to clinical decision-making. Clin Liver Dis. 2015;19:277-294. [PMID: 25921663 DOI: 10.1016/j.cld.2015.01.011] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
106 Collette S, Bonnetain F, Paoletti X, Doffoel M, Bouché O, Raoul J, Rougier P, Masskouri F, Bedenne L, Barbare J. Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials. Annals of Oncology 2008;19:1117-26. [DOI: 10.1093/annonc/mdn030] [Cited by in Crossref: 56] [Cited by in F6Publishing: 62] [Article Influence: 4.0] [Reference Citation Analysis]
107 Pan YX, Chen JC, Fang AP, Wang XH, Chen JB, Wang JC, He W, Fu YZ, Xu L, Chen MS, Zhang YJ, Li QJ, Zhou ZG. A nomogram predicting the recurrence of hepatocellular carcinoma in patients after laparoscopic hepatectomy. Cancer Commun (Lond) 2019;39:55. [PMID: 31601270 DOI: 10.1186/s40880-019-0404-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
108 Cillo U, Vitale A, Grigoletto F, Farinati F, Brolese A, Zanus G, Neri D, Boccagni P, Srsen N, D'amico F, Ciarleglio FA, Bridda A, Francesco D'amico D. Prospective validation of the Barcelona Clinic Liver Cancer staging system. Journal of Hepatology 2006;44:723-31. [DOI: 10.1016/j.jhep.2005.12.015] [Cited by in Crossref: 275] [Cited by in F6Publishing: 259] [Article Influence: 17.2] [Reference Citation Analysis]
109 Gores GJ, Baskin-Bey ES, Baron TH, Alberts SR. Treatment endpoints for advanced cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol 2004;1:4-5. [PMID: 16265019 DOI: 10.1038/ncpgasthep0008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
110 Kudo M, Chung H, Haji S, Osaki Y, Oka H, Seki T, Kasugai H, Sasaki Y, Matsunaga T. Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology. 2004;40:1396-1405. [PMID: 15565571 DOI: 10.1002/hep.20486] [Cited by in Crossref: 243] [Cited by in F6Publishing: 234] [Article Influence: 13.5] [Reference Citation Analysis]
111 Ma S, Ding M, Li J, Wang T, Qi X, Shi Y, Ming Y, Chi J, Wang Z, Tang X, Cui D, Zhang Y, Zhai B. Ultrasound-guided percutaneous microwave ablation for hepatocellular carcinoma: clinical outcomes and prognostic factors. J Cancer Res Clin Oncol 2017;143:131-42. [DOI: 10.1007/s00432-016-2266-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
112 Giakoustidis AE, Giakoustidis DE. Immunosuppression strategies in liver transplantation patient; patients with hepatocellular carcinoma. Immunotherapy 2017;9:197-206. [PMID: 28128716 DOI: 10.2217/imt-2016-0110] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
113 Ray Kim W. The Clip score: is it time to be clipped away? Liver Int 2009;29:2-3. [PMID: 19120937 DOI: 10.1111/j.1478-3231.2008.01913.x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
114 Walling AM, Schreibeis-Baum H, Pimstone N, Asch SM, Robinson L, Korlekar S, Lorenz K, Nwajuaku T, Rosenfeld K. Proactive case finding to improve concurrently curative and palliative care in patients with end-stage liver disease. J Palliat Med 2015;18:378-81. [PMID: 25493552 DOI: 10.1089/jpm.2014.0265] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
115 Talwalkar JA, Gores GJ. Diagnosis and staging of hepatocellular carcinoma. Gastroenterology. 2004;127:S126-S132. [PMID: 15508076 DOI: 10.1053/j.gastro.2004.09.026] [Cited by in Crossref: 88] [Cited by in F6Publishing: 70] [Article Influence: 4.9] [Reference Citation Analysis]
116 El-serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and Treatment of Hepatocellular Carcinoma. Gastroenterology 2008;134:1752-63. [DOI: 10.1053/j.gastro.2008.02.090] [Cited by in Crossref: 690] [Cited by in F6Publishing: 649] [Article Influence: 49.3] [Reference Citation Analysis]
117 Ridruejo E, Mandó OG, Dávalos M, Díaz C, Vilches A. Hepatocellular carcinoma in renal transplant patients. Transplant Proc. 2005;37:2086-2088. [PMID: 15964346 DOI: 10.1016/j.transproceed.2005.03.010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
118 Endo M, Nishikawa H, Kita R, Kimura T, Ohara Y, Sakamoto A, Saito S, Nishijima N, Nasu A, Komekado H, Osaki Y. Comparison of five staging systems in hepatocellular carcinoma treated with sorafenib: A single-center experience. Mol Clin Oncol 2016;4:515-22. [PMID: 27073653 DOI: 10.3892/mco.2016.755] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
119 Carr BI, Pancoska P, Branch RA. Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: a large case cohort study. Hepatol Int. 2010;4:396-405. [PMID: 20305756 DOI: 10.1007/s12072-009-9157-7] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
120 Marrero JA, Kudo M, Bronowicki JP. The challenge of prognosis and staging for hepatocellular carcinoma. Oncologist. 2010;15 Suppl 4:23-33. [PMID: 21115578 DOI: 10.1634/theoncologist.2010-s4-23] [Cited by in Crossref: 79] [Cited by in F6Publishing: 47] [Article Influence: 7.2] [Reference Citation Analysis]
121 Chung H, Kudo M, Takahashi S, Hagiwara S, Sakaguchi Y, Inoue T, Minami Y, Ueshima K, Fukunaga T, Matsunaga T. Comparison of three current staging systems for hepatocellular carcinoma: Japan integrated staging score, new Barcelona Clinic Liver Cancer staging classification, and Tokyo score. J Gastroenterol Hepatol. 2008;23:445-452. [PMID: 17683486 DOI: 10.1111/j.1440-1746.2007.05075.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
122 Huang Y, Chen C, Chang T, Chen S, Wang S, Lee H, Lin P, Huang G, Sheu J, Tsai H, Lee P, Chau G, Lui W, Lee S, Wu J. Evaluation of predictive value of CLIP, Okuda, TNM and JIS staging systems for hepatocellular carcinoma patients undergoing surgery. J Gastroenterol Hepatol 2005;20:765-71. [DOI: 10.1111/j.1440-1746.2005.03746.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 2.5] [Reference Citation Analysis]
123 Lin HH, Hsieh CB, Chu HC, Chang WK, Chao YC, Hsieh TY. Acute pulmonary embolism as the first manifestation of hepatocellular carcinoma complicated with tumor thrombi in the inferior vena cava: surgery or not? Dig Dis Sci. 2007;52:1554-1557. [PMID: 17357843 DOI: 10.1007/s10620-006-9129-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.7] [Reference Citation Analysis]
124 Borbath I, Lhommel R, Bittich L, Goffette P, Annet L, Van Beers BE, Bonny M, Pauwels S, Horsmans Y. 131I-Labelled-iodized oil for palliative treatment of hepatocellular carcinoma: . European Journal of Gastroenterology & Hepatology 2005;17:905-10. [DOI: 10.1097/00042737-200509000-00004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
125 Lange A, Muniraj T, Aslanian HR. Endoscopic Ultrasound for the Diagnosis and Staging of Liver Tumors. Gastrointest Endosc Clin N Am 2019;29:339-50. [PMID: 30846157 DOI: 10.1016/j.giec.2018.12.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
126 Abd El Moety HA, Maharem DA, Gomaa SH. Serotonin: is it a marker for the diagnosis of hepatocellular carcinoma in cirrhotic patients? Alexandria Journal of Medicine 2013;49:369-78. [DOI: 10.1016/j.ajme.2013.03.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
127 Chung H, Kudo M, Takahashi S, Hagiwara S, Sakaguchi Y, Inoue T, Minami Y, Ueshima K, Fukunaga T. Review of current staging systems for hepatocellular carcinoma. Hepatology Research 2007;37:S210-5. [DOI: 10.1111/j.1872-034x.2007.00187.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
128 Sarkodie T, Ross P. Late presentation of sorafenib-associated rash: a case report. J Med Case Rep 2010;4:338. [PMID: 20973944 DOI: 10.1186/1752-1947-4-338] [Reference Citation Analysis]
129 Rabe C, Lenz M, Schmitz V, Pilz T, Fimmers R, Sauerbruch T, Caselmann WH. An independent evaluation of modern prognostic scores in a central European cohort of 120 patients with hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2003;15:1305-15. [PMID: 14624154 DOI: 10.1097/00042737-200312000-00009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
130 Jaruvongvanich V, Sempokuya T, Wong L. Is there an optimal staging system or liver reserve model that can predict outcome in hepatocellular carcinoma? J Gastrointest Oncol 2018;9:750-61. [PMID: 30151272 DOI: 10.21037/jgo.2018.05.11] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
131 Miroux C, Vausselin T, Delhem N. Regulatory T cells in HBV and HCV liver diseases: implication of regulatory T lymphocytes in the control of immune response. Expert Opin Biol Ther 2010;10:1563-72. [PMID: 20932226 DOI: 10.1517/14712598.2010.529125] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 3.2] [Reference Citation Analysis]
132 Chan SL, Mo FK, Wong CS, Chan CM, Leung LK, Hui EP, Ma BB, Chan AT, Mok TS, Yeo W. A study of circulating interleukin 10 in prognostication of unresectable hepatocellular carcinoma. Cancer. 2012;118:3984-3992. [PMID: 22180222 DOI: 10.1002/cncr.26726] [Cited by in Crossref: 38] [Cited by in F6Publishing: 43] [Article Influence: 3.5] [Reference Citation Analysis]
133 Abdel-Rahman O, Elsayed Z. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 2020;1:CD011313. [PMID: 31978267 DOI: 10.1002/14651858.CD011313.pub3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
134 Muros-ortega M, Díaz-carrasco M, Vila-clérigues N, Mendoza-otero F, de la Rubia A, Capel Alemán A. Experiencia de uso de partículas DC Bead® cargadas con doxorrubicina en quimioembolización hepática. Farmacia Hospitalaria 2011;35:172-9. [DOI: 10.1016/j.farma.2010.06.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
135 Geschwind JF, Salem R, Carr BI, Soulen MC, Thurston KG, Goin KA, Van Buskirk M, Roberts CA, Goin JE. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology. 2004;127:S194-S205. [PMID: 15508085 DOI: 10.1053/j.gastro.2004.09.034] [Cited by in Crossref: 241] [Cited by in F6Publishing: 210] [Article Influence: 13.4] [Reference Citation Analysis]
136 Marrero JA. Hepatocellular carcinoma: . Current Opinion in Gastroenterology 2003;19:243-9. [DOI: 10.1097/00001574-200305000-00007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
137 Kubo S, Tanaka H, Shuto T, Takemura S, Yamamoto T, Uenishi T, Tanaka S, Hai S, Yamamoto S, Ichikawa T, Kodai S, Hirohashi K. Prognostic effects of causative virus in hepatocellular carcinoma according to the Japan integrated staging (JIS) score. J Gastroenterol 2005;40:972-9. [PMID: 16261434 DOI: 10.1007/s00535-005-1681-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
138 Omagari K, Honda S, Kadokawa Y, Isomoto H, Takeshima F, Hayashida K, Mizuta Y, Murata I, Kohno S. Preliminary analysis of a newly proposed prognostic scoring system (SLiDe score) for hepatocellular carcinoma. J Gastroenterol Hepatol. 2004;19:805-811. [PMID: 15209629 DOI: 10.1111/j.1440-1746.2004.03350.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
139 Martínez-mier G, Esquivel-torres S, Casanova-sánchez I, Escobar-ríos A, Troche-gutiérrez J, Yoldi-aguirre C. Carcinoma hepatocelular en hígado no cirrótico: características clínicas y resultados en Veracruz, México. Revista de Gastroenterología de México 2021;86:4-12. [DOI: 10.1016/j.rgmx.2019.11.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
140 Samawi HH, Sim HW, Chan KK, Alghamdi MA, Lee-Ying RM, Knox JJ, Gill P, Romagnino A, Batuyong E, Ko YJ, Davies JM, Lim HJ, Cheung WY, Tam VC; CHORD Consortium. Prognosis of patients with hepatocellular carcinoma treated with sorafenib: a comparison of five models in a large Canadian database. Cancer Med 2018. [PMID: 29766659 DOI: 10.1002/cam4.1493] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
141 Seong J, Shim SJ, Lee IJ, Han KH, Chon CY, Ahn SH. Evaluation of the prognostic value of Okuda, Cancer of the Liver Italian Program, and Japan Integrated Staging systems for hepatocellular carcinoma patients undergoing radiotherapy. Int J Radiat Oncol Biol Phys 2007;67:1037-42. [PMID: 17234356 DOI: 10.1016/j.ijrobp.2006.10.035] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
142 Makary MS, Ramsell S, Miller E, Beal EW, Dowell JD. Hepatocellular carcinoma locoregional therapies: Outcomes and future horizons. World J Gastroenterol 2021; 27(43): 7462-7479 [PMID: 34887643 DOI: 10.3748/wjg.v27.i43.7462] [Reference Citation Analysis]
143 Kanayama M, Nagai H, Sumino Y. Influence of the etiology of liver cirrhosis on the response to combined intra-arterial chemotherapy in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 2009;64:109-114. [PMID: 18979100 DOI: 10.1007/s00280-008-0851-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
144 Ikai I, Takayasu K, Omata M, Okita K, Nakanuma Y, Matsuyama Y, Makuuchi M, Kojiro M, Ichida T, Arii S. A modified Japan Integrated Stage score for prognostic assessment in patients with hepatocellular carcinoma. J Gastroenterol. 2006;41:884-892. [PMID: 17048053 DOI: 10.1007/s00535-006-1878-y] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 3.8] [Reference Citation Analysis]
145 Shouval D. HCC: what's the score. Gut 2002;50:749-50. [PMID: 12010872 DOI: 10.1136/gut.50.6.749] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
146 Georgiades CS, Hong K, Geschwind J. Pre- and Postoperative Clinical Care of Patients Undergoing Interventional Oncology Procedures: A Comprehensive Approach to Preventing and Mitigating Complications. Techniques in Vascular and Interventional Radiology 2006;9:113-24. [DOI: 10.1053/j.tvir.2007.01.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
147 Lim H, Ramjeesingh R, Liu D, Tam VC, Knox JJ, Card PB, Meyers BM. Optimizing Survival and the Changing Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review. J Natl Cancer Inst 2021;113:123-36. [PMID: 32898239 DOI: 10.1093/jnci/djaa119] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
148 Obi S, Sato S, Kawai T. Current Status of Hepatic Arterial Infusion Chemotherapy. Liver Cancer. 2015;4:188-199. [PMID: 26674592 DOI: 10.1159/000367746] [Cited by in Crossref: 25] [Cited by in F6Publishing: 30] [Article Influence: 3.6] [Reference Citation Analysis]
149 Dohmen K. Many staging systems for hepatocellular carcinoma: Evolution from Child-Pugh, Okuda to SLiDe. J Gastroenterol Hepatol 2004;19:1227-32. [DOI: 10.1111/j.1440-1746.2004.03538.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
150 Motola-kuba D, Zamora-valdés D, Uribe M, Méndez-sánchez N. Hepatocellular carcinoma. An overview. Annals of Hepatology 2006;5:16-24. [DOI: 10.1016/s1665-2681(19)32034-4] [Cited by in Crossref: 88] [Article Influence: 5.5] [Reference Citation Analysis]
151 Nagano H, Miyamoto A, Wada H, Ota H, Marubashi S, Takeda Y, Dono K, Umeshita K, Sakon M, Monden M. Interferon-alpha and 5-fluorouracil combination therapy after palliative hepatic resection in patients with advanced hepatocellular carcinoma, portal venous tumor thrombus in the major trunk, and multiple nodules. Cancer. 2007;110:2493-2501. [PMID: 17941012 DOI: 10.1002/cncr.23033] [Cited by in Crossref: 67] [Cited by in F6Publishing: 58] [Article Influence: 4.8] [Reference Citation Analysis]
152 Lee S, Han S, Shim JH, Kim SY, Won HJ, Shin YM, Kim PN, An J, Lee D, Kim KM, Lim YS, Chung YH, Lee YS, Lee HC. A Patient-Based Nomogram for Predicting Overall Survival after Radiofrequency Ablation for Hepatocellular Carcinoma. J Vasc Interv Radiol 2015;26:1787-94.e1. [PMID: 26542708 DOI: 10.1016/j.jvir.2015.08.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
153 Farinati F, Sergio A, Giacomin A, Di Nolfo MA, Del Poggio P, Benvegnù L, Rapaccini G, Zoli M, Borzio F, Giannini EG, Caturelli E, Trevisani F; Italian Liver Cancer group. Is female sex a significant favorable prognostic factor in hepatocellular carcinoma? Eur J Gastroenterol Hepatol 2009;21:1212-8. [PMID: 19465859 DOI: 10.1097/MEG.0b013e32831a86f8] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
154 Pons F, Varela M, Llovet JM. Staging systems in hepatocellular carcinoma. HPB (Oxford). 2005;7:35-41. [PMID: 18333159 DOI: 10.1080/13651820410024058] [Cited by in Crossref: 153] [Cited by in F6Publishing: 147] [Article Influence: 12.8] [Reference Citation Analysis]
155 Huang YH, Chen CH, Chang TT, Chen SC, Chiang JH, Lee HS, Lin PW, Huang GT, Sheu JC, Tsai HM, Lee PC, Huo TI, Lee SD, Wu JC. The role of transcatheter arterial embolization for patients with unresectable hepatocellular carcinoma: a nationwide, multicentre study evaluated by cancer stage. Aliment Pharmacol Ther 2005;21:687-94. [PMID: 15771754 DOI: 10.1111/j.1365-2036.2005.02404.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.5] [Reference Citation Analysis]
156 Dilou N, Patouillard B, Audigier JC. [Staging systems in hepatocellular carcinoma]. Gastroenterol Clin Biol 2004;28:359-66. [PMID: 15146151 DOI: 10.1016/s0399-8320(04)94936-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
157 Bargellini I. Hepatocellular carcinoma: MR staging and therapeutic decisions. Abdom Imaging 2012;37:231-8. [PMID: 21479803 DOI: 10.1007/s00261-011-9735-8] [Reference Citation Analysis]
158 Lee JH, Kim HY, Kim YJ, Yoon JH, Chung JW, Lee HS. Barcelona Clinic Liver Cancer staging system and survival of untreated hepatocellular carcinoma in a hepatitis B virus endemic area. J Gastroenterol Hepatol. 2015;30:696-705. [PMID: 25250761 DOI: 10.1111/jgh.12788] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
159 Cammà C, Di Marco V, Cabibbo G, Latteri F, Sandonato L, Parisi P, Enea M, Attanasio M, Galia M, Alessi N, Licata A, Latteri MA, Craxì A. Survival of patients with hepatocellular carcinoma in cirrhosis: a comparison of BCLC, CLIP and GRETCH staging systems. Aliment Pharmacol Ther 2008;28:62-75. [PMID: 18373636 DOI: 10.1111/j.1365-2036.2008.03692.x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 56] [Article Influence: 3.7] [Reference Citation Analysis]
160 Toyoda H, Kumada T, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, Yamaguchi A, Isogai M, Kaneoka Y, Washizu J. Comparison of the usefulness of three staging systems for hepatocellular carcinoma (CLIP, BCLC, and JIS) in Japan. Am J Gastroenterol 2005;100:1764-71. [PMID: 16086713 DOI: 10.1111/j.1572-0241.2005.41943.x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 53] [Article Influence: 3.5] [Reference Citation Analysis]
161 Olthoff KM, Forner A, Hübscher S, Fung J. What is the best staging system for hepatocellular carcinoma in the setting of liver transplantation? Liver Transpl. 2011;17 Suppl 2:S26-S33. [PMID: 21656653 DOI: 10.1002/lt.22352] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]